Contact lens sensor provides 24-hour IOP monitoring

Article

A contact lens sensor is able to provide continuous 24-hour IOP monitoring for the management of glaucoma.

A contact lens sensor is able to provide continuous 24-hour IOP monitoring for the management of glaucoma.

Dr Kaweh Mansouri et al., Hamilton Glaucoma Center, Department of Ophthalmology, University of California San Diego, La Jolla, USA, studied 44 patients with suspected glaucoma or with established glaucoma.,/p>

Patients underwent two 24-hour IOP monitoring sessions, called S1 and S2, at a one-week interval. Pearson correlations were used to assess reproducibility of signal patterns and incidence of adverse events and tolerability were recorded.

The main adverse events were blurred vision in 82% of patients, conjunctival hyperemia in 80% and superficial punctate keratitis in 15%. Mean visual analog score was 27.2 mm in S1 and 23.8 mm S2. The overall correlation between the 2 sessions was 0.59.

The repeated use of the contact lens sensor proved to have good tolerability and safety. The reproducibility was fair to good, meaning that the contact lens sensor can be used for the management process of glaucoma.

The abstract can be found in the Archives of Ophthalmology.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.